Corcept Therapeutics Inc. (NASDAQ:) saw significant trading activity from an insider, according to a recent SEC filing. Joseph Douglas Lyon, the company’s Chief Accounting & Technology Officer, completed both stock purchases and sales on April 4, 2024.
The executive sold a total of 5,443 shares of common stock at prices ranging from $26.00 to $26.01, with the transaction amounting to approximately $141,523. This sale was conducted under a pre-arranged 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks at a specific time.
On the same day, Lyon also exercised options to purchase 5,443 shares of common stock at a price of $11.35 per share, totaling around $61,778. The options were fully exercisable at the time of the transaction.
After these transactions, Lyon’s direct ownership in Corcept Therapeutics includes 7,314 shares of common stock and…
